Tim Illidge
Manchester Academic Health Science Centre(GB)University of Manchester(GB)The Christie NHS Foundation Trust(GB)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immunotherapy and Immune Responses, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade(2014)1,281 cited
- → Consensus guidelines for the definition, detection and interpretation of immunogenic cell death(2020)1,014 cited
- → Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study(2012)983 cited
- → Consensus guidelines for the detection of immunogenic cell death(2014)807 cited
- → Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma(2015)737 cited
- → Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial(2018)710 cited